Top Page
Theriva Biologics
(TOVX)
Theriva Biologics (TOVX) vs. SPDR S&P 500 ETF (SPY)
Theriva Biologics Business Overview & Revenue Model
Theriva Biologics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -27.00K | 0.00 | 0.00 | 0.00 | -87.00K | 0.00 |
| EBITDA | -26.23M | -19.29M | -21.96M | -19.20M | -14.19M | -9.96M |
| Net Income | -26.19M | -25.65M | -18.35M | -19.68M | -14.27M | -10.04M |
Balance Sheet | ||||||
| Total Assets | 30.84M | 35.35M | 55.22M | 71.86M | 70.36M | 8.41M |
| Cash, Cash Equivalents and Short-Term Investments | 7.53M | 11.61M | 23.18M | 41.79M | 67.33M | 6.23M |
| Total Debt | 2.76M | 1.56M | 2.15M | 1.68M | 1.53M | 473.00K |
| Total Liabilities | 24.10M | 16.29M | 15.52M | 17.30M | 4.96M | 3.15M |
| Stockholders Equity | 6.74M | 19.07M | 39.70M | 54.56M | 65.41M | 8.03M |
Cash Flow | ||||||
| Free Cash Flow | -18.51M | -16.94M | -19.20M | -19.20M | -12.90M | -12.18M |
| Operating Cash Flow | -18.48M | -16.94M | -19.00M | -19.08M | -12.89M | -12.17M |
| Investing Cash Flow | -35.00K | -1.00K | -202.00K | -4.40M | -14.00K | -9.00K |
| Financing Cash Flow | 9.74M | 5.50M | 625.00K | -1.93M | 74.00M | 3.36M |
Theriva Biologics Technical Analysis
Theriva Biologics Risk Analysis
Theriva Biologics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $34.85M | -1.93 | -114.81% | ― | ― | 37.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $7.78M | -0.04 | -166.96% | ― | ― | 83.25% | |
45 Neutral | $4.16M | -0.22 | -157.24% | ― | ― | 25.19% | |
44 Neutral | $4.58M | -0.24 | -46.34% | ― | ― | 70.71% | |
42 Neutral | $3.73M | -0.11 | -197.11% | ― | ― | 99.87% |
Theriva Biologics Corporate Events
Theriva Biologics has updated investors on progress preparing a Phase 3 clinical trial for its lead oncolytic virus VCN-01 in first-line metastatic pancreatic cancer, supported by encouraging Phase 2b VIRAGE data showing improved overall and progression-free survival, longer duration of response, and an acceptable safety profile when VCN-01 is added to standard gemcitabine/nab-paclitaxel chemotherapy in a real-world patient population. The company is also advancing VCN-01 in retinoblastoma and other solid tumor indications, reporting multiple regulatory designations in the U.S. and EU, a projected cash runway into the first quarter of 2027, and an active search for financing or partnerships, developments that collectively underscore its bid to strengthen its position in the competitive cancer therapeutics market and to move toward pivotal-stage programs in high-mortality and rare disease settings.
The most recent analyst rating on (TOVX) stock is a Sell with a $0.24 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.
On December 29, 2025, Theriva Biologics reported that it received positive Scientific Advice from the European Medicines Agency’s Committee for Medicinal Products for Human Use on the design of a pivotal Phase 3 trial of its lead oncolytic adenovirus candidate VCN-01 in combination with gemcitabine/nab-paclitaxel as first-line therapy for metastatic pancreatic ductal adenocarcinoma. The agency broadly endorsed Theriva’s plan for a single, double-blind, randomized, placebo-controlled Phase 3 study using overall survival as the primary endpoint, key secondary endpoints such as progression-free survival and duration of response, an adaptive trial design, and a repeated “macrocycle” dosing regimen that allows more than two doses of VCN-01, reflecting survival benefits seen in the prior VIRAGE Phase 2b trial. Theriva, which held $15.5 million in cash as of November 10, 2025 and projects runway into the first quarter of 2027, plans an End-of-Phase 2 meeting with the U.S. FDA in the first half of 2026 to finalize a multinational Phase 3 protocol, with regulatory clarity expected to support partnering, manufacturing scale-up, and potential expansion of VCN-01 development into retinoblastoma, thereby sharpening the company’s late-stage oncology profile.
The most recent analyst rating on (TOVX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.
On December 15, 2025, Theriva Biologics was unable to convene its Special Meeting of Stockholders due to insufficient shares present to constitute a quorum. Consequently, the company will reschedule the meeting to seek approval for a warrant exercise proposal, as required under a warrant inducement agreement with institutional investors. This agreement mandates that Theriva Biologics continues to call stockholder meetings every 60 days until approval is obtained or the warrants are no longer outstanding.
The most recent analyst rating on (TOVX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.
On October 20, 2025, Theriva Biologics presented expanded data from their VIRAGE Phase 2b trial at the ESMO 2025 Annual Congress. The trial evaluates the efficacy of VCN-01 combined with standard chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Results indicate that VCN-01, when used with standard care, shows promising improvements in progression-free survival and overall response rates, potentially enhancing treatment outcomes for this aggressive cancer.
The most recent analyst rating on (TOVX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.
On October 16, 2025, Theriva Biologics entered into a warrant inducement agreement with existing institutional investors, resulting in the exercise of warrants to purchase up to 7,360,460 shares of common stock at a reduced price, generating approximately $4.0 million in gross proceeds. The company issued new warrants for additional shares, set to be exercisable upon stockholder approval, with the proceeds intended for working capital and corporate purposes. This transaction, advised by A.G.P./Alliance Global Partners, is expected to impact Theriva’s operational liquidity and strategic positioning in the biotech industry.
The most recent analyst rating on (TOVX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.
On October 13, 2025, Theriva Biologics announced the presentation of expanded data from the VIRAGE Phase 2b trial on metastatic pancreatic ductal adenocarcinoma (mPDAC) at the ESMO 2025 Congress. The trial results indicated that patients receiving VCN-01 in combination with standard chemotherapy showed improved overall survival, progression-free survival, and duration of response compared to chemotherapy alone. The administration of VCN-01 was well tolerated, with all related serious adverse events resolved. These findings could enhance Theriva’s positioning in the oncology field by demonstrating the potential efficacy of VCN-01 in treating mPDAC.
The most recent analyst rating on (TOVX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.